Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies

Inclusion Criteria: 1. Participants voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up. 2. 18\~80 years old. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. With evaluable tumor lesion. 5. Relapsed and/or refractory hematologic malignancies (Non-Hodgkin Lymphoma or Multiple Myeloma). 6. Life expectancy≥ 3 months. 7. Clinical laboratory values meet screening visit criteria. 8. Adequate organ function. Exclusion Criteria: 1. Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy. 2. Prior antitumor therapy with insufficient washout period. 3. Known life-threatening allergic reaction, hypersensitivity reaction, or intolerance to study drug excipients and related excipients, including but not limited to DMSO; or those with a history of severe allergic reactions in the past (such as hypersensitivity reactions, or those with severe immune-related reactions such as the need for glucocorticoids to prevent anaphylaxis as assessed by the investigator). 4. Lactating women.